NASDAQ$PMVP
Pmv Pharmaceuticals Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2024.
PMV Pharma reported first quarter financial results, highlighting the dosing of the first patient in the Phase 2 portion of the PYNNACLE trial and a cash, cash equivalents, and marketable securities balance of $213.1 million as of March 31, 2024.
- First patient dosed in Phase 2 portion of the PYNNACLE trial assessing rezatapopt as monotherapy.
- Phase 1 data of rezatapopt in advanced ovarian cancer featured at the 2024 SGO Annual Meeting on Women’s Cancer.
- Cash, cash equivalents, and marketable securities totaled $213.1 million as of March 31, 2024, providing an expected cash runway to the end of 2026.
- Net loss for the quarter ended March 31, 2024, was $15.3 million.
Headline financials
Revenue & EPS history
PMV Pharma · Revenue · Quarterly
$0
Forward guidance
The company provided forward-looking statements regarding their future plans and expectations for rezatapopt, including the ability to obtain approval as a treatment option and the timing and success of the Phase 2 portion of the current clinical trial.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+2.7%
Avg return
Earnings day
+3.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
67%
14 / 21 earnings
Positive
+29.5%
Q2 2023
Best reaction
-18.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.0% | +8.0% | -10.7% | |
| Q3 2025 | +8.5% | +6.8% | -7.5% | |
| Q2 2025 | -4.1% | -6.6% | -3.9% | |
| Q1 2025 | +4.2% | +7.5% | +28.9% | |
| Q4 2024 | -3.6% | -10.2% | -27.0% | |
| Q3 2024 | +4.8% | +0.6% | -4.2% | |
| Q1 2024 | -5.6% | -0.9% | -23.1% | |
| Q4 2023 | +3.9% | +3.9% | -6.1% | |
| Q3 2023 | +7.5% | +19.9% | +24.2% | |
| Q2 2023 | +29.5% | +20.0% | -10.8% | |
| Q1 2023 | +11.9% | +14.7% | +8.5% | |
| Q4 2022 | -18.1% | -19.6% | -33.8% | |
| Q3 2022 | -3.7% | +11.2% | -2.6% | |
| Q2 2022 | +0.4% | -1.3% | -17.6% | |
| Q1 2022 | +2.2% | +9.0% | -13.7% | |
| Q4 2021 | +10.3% | +1.3% | +31.4% | |
| Q3 2021 | +0.4% | +2.4% | -1.6% | |
| Q2 2021 | -1.2% | -5.2% | -10.2% | |
| Q1 2021 | +12.7% | +15.6% | +18.5% | |
| Q4 2020 | +0.7% | -0.7% | -5.9% | |
| Q3 2020 | -5.1% | -5.2% | +40.3% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro